<DOC>
	<DOCNO>NCT02262663</DOCNO>
	<brief_summary>This study healthy woman reproductive age investigate pharmacodynamics ( mainly ovarian activity ) , pharmacokinetics safety vilaprisan daily oral administration 4 different dos 84 day , use randomize , parallel-group , multicenter design .</brief_summary>
	<brief_title>Study Healthy Young Women Investigate Pharmacodynamics , Pharmacokinetics Safety Vilaprisan</brief_title>
	<detailed_description />
	<criteria>Body mass index ( BMI ) : ≥ 18 ≤ 32 kg/m² first screen visit Absence clinically relevant abnormal finding pretreatment endometrial biopsy Pretreatment cycle assess ovulatory longer 44 day Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Known suspect liver disorder Amenorrhea 3 month within last 6 month first screen examination Clinically relevant finding ( e.g . blood pressure , electrocardiogram [ ECG ] , physical gynecological examination , laboratory examination ) Positive urine pregnancy test Regular use medicine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>